Highlights
Profile claimed by owner
About
Inhibitors for Cancer Treatment
Pi Therapeutics is a preclinical-stage pharmaceutical company dedicated to the development of protein degradation modulators for the treatment of cancer. The companys lead drug modulates pathways related to proteostasis, offering a unique approach to the preferential targeting of cancer cells. Preclinical data to date have demonstrated a compelling safety and efficacy profile which is differentiated from approved protein degradation inhibitors. The company targets hematologic as well as solid tumor indications and expects to initiate clinical studies next year. Pi Therapeutics was founded based on technology in-licensed from Johns Hopkins University.
Identity
| Name | Pi Therapeutics |
|---|---|
| Slug | pi-therapeutics |
| Type / kind | startup |
| Crunchbase ID | pi-therapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMWF04oKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Apr 2023 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Netanya |
| HQ address | HaMelacha St 45, Netanya, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
drug-discoverybiopharmaceuticalpharma-companiescancer
Funding
| Total raised | $19.7M |
|---|---|
| Current stage | Series B |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}